RE:RE:wow, what a great day....That's what I see, so it's back to accumulating when possible for the next 3 months.
enriquesuave wrote: I don't know what the market expected, but we knew that we would only get the same data as last Q report plus patients 13-15. So far the treatment is showing at least 6 months durability just when patients will get treated a second time with an optimized treatment. As for 13-15 so far 2 out of 3 are CR. Not bad. Just need more data, and even if we just get good news from those pending and maybe clarify the partial responders, then market will have a better idea of efficacy potential. We are still negatively affected by the under treatment of the first set of 12 and not enough new data. IMO